# Enhancing Cancer Therapy with Hyperthermia: Synergistic Effects with Natural Compounds and Conventional Treatments

**Authors:** Nada Oršolić, Darko Kučan, Maja Jazvinšćak Jembrek

PMC · DOI: 10.3390/ijms27041650 · International Journal of Molecular Sciences · 2026-02-08

## TL;DR

Hyperthermia boosts cancer treatments by working with natural compounds and conventional therapies to improve drug uptake, reduce resistance, and enhance cell death.

## Contribution

The paper highlights the novel synergistic effects of hyperthermia with natural compounds like propolis and flavonoids in cancer therapy.

## Key findings

- Hyperthermia increases tumor membrane permeability and drug uptake while reducing hypoxia-induced resistance.
- Natural compounds like propolis and flavonoids enhance ROS generation and modulate the tumor microenvironment when combined with hyperthermia.
- Hyperthermia downregulates proangiogenic factors like TGF-β1, VEGF, and MMP-2/9, reducing tumor progression.

## Abstract

Hyperthermia (HT) is a promising adjunct to conventional cancer therapies such as chemotherapy and radiotherapy (RT). It offers several advantages, including low toxicity to normal tissues, limited tumor resistance, and synergistic therapeutic effects. HT enhances treatment efficacy by inhibiting DNA repair mechanisms, increasing tumor membrane permeability for improved drug uptake, and improving oxygenation to reduce hypoxia-induced resistance. HT also promotes cancer cell death by inducing oxidative stress, leading to mitochondrial dysfunction, caspase activation, and PARP cleavage. It causes G2/M cell cycle arrest and damages tumor vasculature. Additionally, HT downregulates proangiogenic and invasive factors such as TGF-β1, VEGF, and MMP-2/9, contributing to reduced tumor progression. Combining HT with natural compounds like propolis and flavonoids further improves therapeutic outcomes. These natural agents are accessible, cost-effective, and exhibit multi-targeted anticancer activity. In synergy with HT, they enhance reactive oxygen species (ROS) generation, suppress heat shock proteins, modulate the tumor microenvironment (TME), and activate immune responses. They may also reduce the side effects of conventional therapies and support tissue regeneration. Overall, HT, especially in combination with natural compounds, offers a multifaceted and effective approach to cancer therapy.

## Linked entities

- **Proteins:** PARP1 (poly(ADP-ribose) polymerase 1), TGFB1 (transforming growth factor beta 1), VEGFA (vascular endothelial growth factor A), MMP2 (matrix metallopeptidase 2), MMP9 (matrix metallopeptidase 9)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, Cat (catalase) [NCBI Gene 12359] {aka 2210418N07, Cas-1, Cas1, Cs-1}, CCR7 (C-C motif chemokine receptor 7) [NCBI Gene 1236] {aka BLR2, CC-CKR-7, CCR-7, CD197, CDw197, CMKBR7}, FGFR4 (fibroblast growth factor receptor 4) [NCBI Gene 2264] {aka CD334, JTK2, TKF}, ESR2 (estrogen receptor 2) [NCBI Gene 2100] {aka ER-BETA, ESR-BETA, ESRB, ESTRB, Erb, NR3A2}, JAK1 (Janus kinase 1) [NCBI Gene 397202], IL22 (interleukin 22) [NCBI Gene 50616] {aka IL-21, IL-22, IL-D110, IL-TIF, ILTIF, TIFIL-23}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, TNFSF10 (TNF superfamily member 10) [NCBI Gene 8743] {aka APO2L, Apo-2L, CD253, TANCR, TL2, TNLG6A}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, HSP90AB1 (heat shock protein 90 alpha family class B member 1) [NCBI Gene 3326] {aka D6S182, HSP84, HSP90B, HSPC2, HSPCB}, FASLG (Fas ligand) [NCBI Gene 356] {aka ALPS1B, APT1LG1, APTL, CD178, CD95-L, CD95L}, SLA-DRB1 (MHC class II histocompatibility antigen SLA-DRB1) [NCBI Gene 100153386] {aka DRB1, LA-DRB-c, LA-DRB-d, SLA-DRB, SLADRB}, HSPA1A (heat shock protein family A (Hsp70) member 1A) [NCBI Gene 3303] {aka HEL-S-103, HSP70, HSP70-1, HSP70-1A, HSP70-2, HSP70.1}, LDHA (lactate dehydrogenase A) [NCBI Gene 3939] {aka GSD11, HEL-S-133P, LDHM, PIG19}, FLT1 (fms related receptor tyrosine kinase 1) [NCBI Gene 2321] {aka FLT, FLT-1, VEGFR-1, VEGFR1}, CDK9 (cyclin dependent kinase 9) [NCBI Gene 1025] {aka C-2k, CDC2L4, CTK1, PITALRE, TAK}, PGF (placental growth factor) [NCBI Gene 5228] {aka D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760}, APAF1 (apoptotic peptidase activating factor 1) [NCBI Gene 317] {aka APAF-1, CED4}, HSPA4 (heat shock protein family A (Hsp70) member 4) [NCBI Gene 3308] {aka APG-2, HEL-S-5a, HS24/P52, HSPH2, RY, hsp70}, KLRC2 (killer cell lectin like receptor C2) [NCBI Gene 3822] {aka CD159c, NKG2-C, NKG2C}, SEMA4D (semaphorin 4D) [NCBI Gene 10507] {aka A8, BB18, C9orf164, CD100, COLL4, GR3}, MDM2 (MDM2 proto-oncogene) [NCBI Gene 4193] {aka ACTFS, HDMX, LSKB, hdm2}, HSF1 (heat shock transcription factor 1) [NCBI Gene 3297] {aka HSTF1}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, Bax (BCL2-associated X protein) [NCBI Gene 12028], CSF3 (colony stimulating factor 3) [NCBI Gene 1440] {aka C17orf33, CSF3OS, GCSF}, MMP14 (matrix metallopeptidase 14) [NCBI Gene 4323] {aka MMP-14, MMP-X1, MT-MMP, MT-MMP 1, MT1-MMP, MT1MMP}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, Cybb (cytochrome b-245, beta polypeptide) [NCBI Gene 13058] {aka CGD91-phox, Cgd, Cyd, Nox2, gp91-1, gp91phox}, PLXNB1 (plexin B1) [NCBI Gene 5364] {aka PLEXIN-B1, PLXN5, SEP}, C4B (complement C4B (Chido/Rodgers blood group)) [NCBI Gene 721] {aka C4B1, C4B12, C4B3, C4B5, C4BD, C4F}, IFNG (interferon gamma) [NCBI Gene 396991], PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, ODC1 (ornithine decarboxylase 1) [NCBI Gene 4953] {aka BABS, NEDBA, NEDBIA, ODC}, XIAP (X-linked inhibitor of apoptosis) [NCBI Gene 331] {aka API3, BIRC4, IAP-3, ILP1, MIHA, XLP2}, LOXL2 (lysyl oxidase like 2) [NCBI Gene 4017] {aka LOR, LOR2, WS9-14}, PFKM (phosphofructokinase, muscle) [NCBI Gene 5213] {aka ATP-PFK, GSD7, PFK-1, PFK-A, PFK1, PFKA}, Crp (C-reactive protein, pentraxin-related) [NCBI Gene 12944], IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, PKM (pyruvate kinase M1/2) [NCBI Gene 5315] {aka CTHBP, HEL-S-30, OIP3, PK3, PKM2, TCB}, E2F4 (E2F transcription factor 4) [NCBI Gene 1874] {aka E2F-4}, NOLC1 (nucleolar and coiled-body phosphoprotein 1) [NCBI Gene 9221] {aka NOPP130, NOPP140, NS5ATP13, P130, Srp40}, CCNB1 (cyclin B1) [NCBI Gene 891] {aka CCNB}, Hmox1 (heme oxygenase 1) [NCBI Gene 15368] {aka D8Wsu38e, HO-1, HO1, Hemox, Hmox, Hsp32}, CCL22 (C-C motif chemokine ligand 22) [NCBI Gene 6367] {aka A-152E5.1, ABCD-1, DC/B-CK, MDC, SCYA22, STCP-1}, JUND (JunD proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3727] {aka AP-1}, MICA (MHC class I polypeptide-related sequence A) [NCBI Gene 100507436] {aka MIC-A, PERB11.1}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}
- **Diseases:** HSPs (MESH:D012769), gastric ulcers (MESH:D013276), injury (MESH:D014947), diseases (MESH:D004194), inflammation (MESH:D007249), osteosarcoma (MESH:D012516), glioma (MESH:D005910), melanoma (MESH:D008545), metal (MESH:D013651), platelet aggregation (MESH:D001791), prostate cancer (MESH:D011471), pain (MESH:D010146), cervical cancer (MESH:D002583), EAT (MESH:D002286), MDR (MESH:D018088), skin (MESH:D012871), pancreatic cancer (MESH:D010190), Mitochondrial dysfunction (MESH:D028361), fibrosarcoma (MESH:D005354), lung cancer (MESH:D008175), neurotoxicity (MESH:D020258), PC (MESH:D010534), urothelial (MESH:D014526), Vascular abnormalities (MESH:D014652), diabetes (MESH:D003920), thermal (MESH:D020886), Cancer (MESH:D009369), head and neck cancer (MESH:D006258), skin cancer (MESH:D012878), Hypoxic (MESH:D002534), viremia (MESH:D014766), lymphoid leukemia (MESH:D007945), Hodgkin's lymphoma (MESH:D006689), HIPEC (MESH:D000084202), diarrhea (MESH:D003967), hyperemia (MESH:D006940), carcinogenesis (MESH:D063646), ischemia (MESH:D007511), Merkel cell carcinoma (MESH:D015266), HT (MESH:D005334), oral squamous carcinoma (MESH:D000077195), maxillary carcinoma (MESH:D008441), NSCLC (MESH:D002289), colon carcinoma (MESH:D003110), burns (MESH:D002056), hypoxia (MESH:D000860), hypothermia (MESH:D007035), vascular collapse (MESH:D001261), lung metastases (MESH:D009362), tumorigenicity (MESH:D002471), neutropenia (MESH:D009503), carcinogenic (MESH:D011230), sore throats (MESH:D010612), pleural synovial sarcoma (MESH:D013584), abdominal tumors (MESH:D000008), colon cancer (MESH:D015179), viral infection (MESH:D014777), leukemia (MESH:D007938), PTT (MESH:D016609), cardiovascular disorders (MESH:D002318)
- **Chemicals:** platinum (MESH:D010984), Metal (MESH:D008670), silymarin (MESH:D012838), Ferrlecit (MESH:C035552), EGCG (MESH:C045651), galangin (MESH:C037032), 1,3-bis(2-chloroethyl)-1-nitrosourea (MESH:D002330), gold (MESH:D006046), diosmin (MESH:D004145), chitosan (MESH:D048271), flavone (MESH:C043562), sodium alginate (MESH:D000464), chrysin (MESH:C043561), 8-oxo-dGTP (MESH:C078206), molecular oxygen (MESH:D010100), pidilizumab (MESH:C585832), zinc (MESH:D015032), eupatorin (MESH:C103110), lactate (MESH:D019344), NO2- (MESH:D009585), dorsomorphin (MESH:C516138), tamoxifen (MESH:D013629), nickel (MESH:D009532), Nobiletin (MESH:C008661), PEG (MESH:D011092), hesperidin (MESH:D006569), prostaglandins (MESH:D011453), PTX (MESH:D017239), pomiferin (MESH:C474837), IRI (MESH:D000077146), beta-cyclodextrin (MESH:C031215), QU (MESH:D011794), sulforaphane (MESH:C016766), Res (MESH:D012211), dityrosine (MESH:C007543), pentose phosphate (MESH:D010428), polymers (MESH:D011108), PAM (MESH:C016679), axillarin (MESH:C056669), hesperetin (MESH:C013015), 5-FU (MESH:D005472), curcuminoid (MESH:D036381), tyrosine (MESH:D014443), phenol (MESH:D019800), palladium (MESH:D010165), water (MESH:D014867), methotrexate (MESH:D008727), PGA (MESH:D011100), free radicals (MESH:D005609), Kaempferol (MESH:C006552), PMMA (MESH:D019904), myricetin (MESH:C040015), phenolic acids (MESH:C017616), Fe (MESH:D007501), ferulic acid (MESH:C004999), cantharidin (MESH:D002193), catechins (MESH:D002392), genistein (MESH:D019833), terpenoids (MESH:D013729), prostaglandin E2 (MESH:D015232)
- **Species:** Haematoxylum campechianum (species) [taxon 321551], Mus musculus (house mouse, species) [taxon 10090], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Echinacea angustifolia (black sampson, species) [taxon 308558], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Curcuma longa (turmeric, species) [taxon 136217], gut metagenome (species) [taxon 749906], Apis mellifera (bee, species) [taxon 7460]
- **Cell lines:** M10 — Mus musculus (Mouse), Mouse thymic lymphoma, Cancer cell line (CVCL_L285), Chinese hamster ovarian carcinoma — Cricetulus griseus (Chinese hamster), Spontaneously immortalized cell line (CVCL_0212), HL-60 — Homo sapiens (Human), Adult acute myeloid leukemia with maturation, Cancer cell line (CVCL_0002), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), CT26 — Mus musculus (Mouse), Mouse colon adenocarcinoma, Cancer cell line (CVCL_7254), B16-F10 — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_0159), HCT-116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), DU-145 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0105), C26 cancer — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_E025), 4T1 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_0125), C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU), Balb/c — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184), Panc02 — Mus musculus (Mouse), Mouse pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_D627), OvCa — Homo sapiens (Human), Ovarian adenocarcinoma, Cancer cell line (CVCL_A8KH), Sk-Hep1 — Homo sapiens (Human), Liver and intrahepatic bile duct epithelial neoplasm, Cancer cell line (CVCL_0525), PANC-1 — Homo sapiens (Human), Pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_0480), T24 — Homo sapiens (Human), Bladder carcinoma, Cancer cell line (CVCL_0554), RT4 — Homo sapiens (Human), Bladder carcinoma, Cancer cell line (CVCL_0036), PC-3 — Cirrhinus mrigala (Mrigala), Spontaneously immortalized cell line (CVCL_A2ZP), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), M14 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_1395), UMUC — Homo sapiens (Human), Bladder carcinoma, Cancer cell line (CVCL_2743), MNT1 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_5624)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940534/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940534/full.md

## References

313 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940534/full.md

---
Source: https://tomesphere.com/paper/PMC12940534